Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens cadherin 1, type 1, E-cadherin (epithelial) (CDH1)
Synonyms:
Arc-1; CD324; CDHE; ECAD; LCAM; UVO
Immunogen
A phospho-specific peptide corresponding to residues surrounding serine 838/840 of human E-cadherin was used as an immunogen. This antibody detects E-cadherin phosphorylated at serine 838 and 840
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
E-Cadherin, a member of the cadherin superfamily, is implicated as a key player in different cellular processes including development, morphology, polarity, migration and tissue integrity (1-2). E-cadherin is a glycoprotein with an extracellular domain that interacts with other E-cadherin molecules on adjacent cells, thereby establishing adhesion between epithelial cells. Established as a tumor and metastasis suppressor, E-cadherin expression is frequently down-regulated or extinguished in malignancy which strongly correlates with poor prognosis (3-4). Mutations in E-cadherin are found in gastric, breast, colorectal, thyroid and ovarian cancer (5).
Related Pathway
Adherens junction
Wnt Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on human brain lysates using anti-Phospho-E-Cadherin (pS838/840), 1:1,000,000 dilution. Cells were either (A) untreated (B) treated with AP
